Nutritional supplement for treatment of cancer cachexia
    11.
    发明授权
    Nutritional supplement for treatment of cancer cachexia 失效
    用于治疗癌症恶病质的营养补充剂

    公开(公告)号:US4906664A

    公开(公告)日:1990-03-06

    申请号:US144930

    申请日:1988-01-15

    IPC分类号: A61K31/23

    CPC分类号: A61K31/23

    摘要: A method of treating cancer cachexia syndrome has been discovered. Total parenteral nutrition using structured lipids in place of long chain fatty acids as the primary lipid source provides improvements in nitrogens balance, plasma serum albumin levels, and glucose clearance rate.

    摘要翻译: 已经发现了治疗癌症恶病质综合征的方法。 使用结构化脂质代替长链脂肪酸作为主要脂质源的全肠外营养提供了氮的平衡,血浆血清白蛋白水平和葡萄糖清除率的改善。

    Treatment of protein malnourished surgical patients
    12.
    发明授权
    Treatment of protein malnourished surgical patients 失效
    治疗蛋白质营养不良的手术患者

    公开(公告)号:US4512974A

    公开(公告)日:1985-04-23

    申请号:US447984

    申请日:1982-12-08

    CPC分类号: C07K14/545 A61K38/00

    摘要: Exogenous LEM (Leukocyte Endogenous Mediator, also referred to as endogenous pyrogen) is parenterally administered to humans who are protein malnourished and are to undergo surgery, in order to preinitiate and then maintain the normal metabolic responses to the tissue damage occurring during surgery, and thereby promote the normal metabolic response by the human (patient).

    摘要翻译: 外源性LEM(白细胞内源性调解子,也称为内源性热原)被肠胃外施用于蛋白质营养不良并将进行手术的人,以便预先诱导并且然后维持对在手术期间发生的组织损伤的正常代谢反应,由此 促进人(病人)的正常代谢反应。

    Method and composition for testing patients with metabolic depleting
diseases
    14.
    发明授权
    Method and composition for testing patients with metabolic depleting diseases 失效
    用于测试代谢性衰竭疾病患者的方法和组成

    公开(公告)号:US5320846A

    公开(公告)日:1994-06-14

    申请号:US965609

    申请日:1992-10-22

    IPC分类号: A61K9/00 A61K47/00

    摘要: A method of treating patients with clinical disorder involving splanchnic disorders such as liver or gut dysfunction, the dysfunction being characterized by depletion of metabolic energy sources. The treatment involves the step of administering an effective amount of adenosine, or related nucleosides, to achieve and/or maintain normal metabolic levels of adenosine triphosphate (ATP) and/or its precursors in the patient's liver or other splanchnic organs. Administration may be as a total enteral nutritional diet, or as a dietary supplement. The invention includes a total enteral nutrition diet having nutritionally acceptable amounts of a lipid source, a protein source, a carbohydrate source, a vitamin source, and a mineral source, and an effective amount of adenosine to achieve normal metabolic levels of ATP and/or its precursors in ATP deficient organs of a recipient host.

    摘要翻译: 一种治疗涉及内脏病例如肝脏或肠道功能障碍的临床病症的患者的方法,其功能障碍的特征在于代谢能源的消耗。 治疗涉及施用有效量的腺苷或相关核苷以达到和/或维持患者肝脏或其它内脏器官中三磷酸腺苷(ATP)和/或其前体的正常代谢水平的步骤。 管理可能是一种全面的肠内营养饮食,或作为膳食补充剂。 本发明包括具有营养可接受量的脂质源,蛋白质来源,碳水化合物源,维生素源和矿物源的总肠内营养饮食和有效量的腺苷以实现ATP和/或的正常代谢水平 其前体在受体宿主的ATP缺乏器官中。

    Kernel oils and disease treatment
    18.
    发明授权
    Kernel oils and disease treatment 失效
    内脏油和疾病治疗

    公开(公告)号:US4810726A

    公开(公告)日:1989-03-07

    申请号:US33346

    申请日:1987-04-01

    摘要: A method of treating, and a diet composition for treating patients needing a controlled diet, wherein C.sub.12 fatty acids are the primary fatty acid source. Preferably lauric fats constitute 33-80% of the diet, while LCT's constitute no more than 20%. The lauric fats may be derived from a natural or fractionated kernel oil, selected from a group consisting of babassu oil, coconut oil, cohune oil, palm kernel oil, and tucum oil. A lipid emulsion with diverse additives is described.

    摘要翻译: 一种治疗方法和用于治疗需要受控饮食的患者的饮食组合物,其中C12脂肪酸是主要的脂肪酸来源。 最好是月桂脂肪占饮食的33-80%,而LCT则不超过20%。 月桂酸脂肪可以衍生自选自巴巴苏油,椰子油,椰子油,棕榈仁油和土豆油的天然或分馏的仁油。 描述了具有不同添加剂的脂质乳剂。

    Dietary formulation comprising arachidonic acid and methods of use
    20.
    发明授权
    Dietary formulation comprising arachidonic acid and methods of use 失效
    含花生四烯酸的饮食配方及其使用方法

    公开(公告)号:US5993221A

    公开(公告)日:1999-11-30

    申请号:US847036

    申请日:1997-05-01

    申请人: Bruce R. Bistrian

    发明人: Bruce R. Bistrian

    摘要: A novel formulation which contains about 2-60% by calories of a C.sub.20 or longer .omega.3 fatty acid moiety and about 2-60% by calories of an arachidonic acid moiety has been developed. This formulation is particularly useful for restoring arachidonic acid levels, increasing immunity or minimizing risk of infection in critically ill patients, and treating functional essential fatty acid deficiency in patients suffering from end stage liver disease. A structured lipid which has a C.sub.20 or longer .omega.3 fatty acid moiety and an arachidonic acid moiety has also been developed.

    摘要翻译: 已经开发了一种新的制剂,其通过卡路里含有约2-60%的C20或更长的ω-3脂肪酸部分和约2-60%的卡路里的花生四烯酸部分。 该制剂对于恢复花生四烯酸水平,增加免疫力或最小化危重病人感染风险以及治疗终末期肝病患者功能性必需脂肪酸缺乏症特别有用。 还开发了具有C20或更长的ω-3脂肪酸部分和花生四烯酸部分的结构化脂质。